FREMONT, Calif., Oct. 10, 2019 /PRNewswire/ -- Ardelyx, Inc.
(Nasdaq: ARDX), today announced that it will hold an Analyst Day on
Thursday, Oct. 17, 2019, from
7:30 a.m. to 11:00 a.m. ET in
New York City. This year's event
will focus on a review of late stage clinical development and
commercial potential in hyperphosphatemia, pipeline program in
hyperkalemia and the recent approval of the Company's New Drug
Application for tenapanor for the treatment of IBS-C. Leading
nephrologist, Myles Wolf, M.D.,
Chief of Nephrology, Duke University,
will offer a clinician's perspective on the challenges of treating
hyperphosphatemia in patients with CKD on dialysis.
A live webcast of the event will be available for 30 days on the
Events and Presentations page under the investor relations section
of Ardelyx's website at www.ardelyx.com.
About Ardelyx, Inc.
Ardelyx is focused on enhancing
the lives of people with cardiorenal diseases by developing
first-in-class medicines that matter. Ardelyx's cardiorenal
pipeline includes the Phase 3 development of tenapanor for the
treatment of hyperphosphatemia in people with CKD on dialysis, and
RDX013, a potassium secretagogue program for the potential
treatment of high potassium, or hyperkalemia, a problem among
certain patients with kidney and/or heart disease. On September 3, 2019, the company reported positive
data from AMPLIFY, a pivotal Phase 3 study investigating tenapanor
in combination with phosphate binders in patients with chronic
kidney disease on dialysis whose hyperphosphatemia was not
previously controlled with binders alone. The study successfully
met the primary endpoint and all key secondary endpoints, including
demonstrating a statistically significant mean reduction in serum
phosphorus from baseline to the end of the treatment period. On
September 12, 2019, Ardelyx received
approval of IBSRELA (tenapanor) for the treatment of irritable
bowel syndrome with constipation (IBS-C). To efficiently bring its
treatments to market, Ardelyx is pursuing strategic collaborations
for IBSRELA for IBS-C and tenapanor for hyperphosphatemia in
certain territories. Ardelyx has established agreements with Kyowa
Kirin Company Limited in Japan,
Fosun Pharma in China and Knight
Therapeutics in Canada. For more
information, please visit http://www.ardelyx.com and connect with
us on Twitter @Ardelyx.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ardelyx-to-host-analyst-day-in-new-york-300936766.html
SOURCE Ardelyx